Disc Medicine (NASDAQ:IRON) Earns Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Disc Medicine (NASDAQ:IRON) in a report released on Tuesday,RTT News reports. Wedbush currently has a $83.00 price target on the stock, up from their prior price target of $75.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.94) EPS, Q1 2025 earnings at ($0.98) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($4.19) EPS, FY2027 earnings at $2.20 EPS and FY2028 earnings at $7.04 EPS.

Several other equities research analysts have also recently issued reports on IRON. Jefferies Financial Group initiated coverage on Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Disc Medicine in a research report on Tuesday, November 5th. Scotiabank increased their price objective on Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Finally, Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Disc Medicine currently has a consensus rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Trading Down 2.0 %

IRON stock opened at $59.46 on Tuesday. The business’s 50-day moving average is $51.20 and its 200 day moving average is $44.97. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $77.60. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15. As a group, equities analysts forecast that Disc Medicine will post -4.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 7,538 shares of company stock valued at $437,875. 4.24% of the stock is owned by company insiders.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently bought and sold shares of IRON. Amalgamated Bank grew its holdings in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Disc Medicine in the 2nd quarter valued at about $129,000. Quest Partners LLC purchased a new position in Disc Medicine during the 3rd quarter valued at about $131,000. Finally, Quantbot Technologies LP acquired a new position in Disc Medicine during the third quarter worth about $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.